Zacks Investment Research
01 Sept 2026, 15:46 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Medtronic reported Q1 fiscal 2027 adjusted EPS of $1.45, a 15.1% year-over-year increase that beat consensus estimates by 4.32%. — Earnings beats and strong YoY growth typically drive immediate positive price action, as evidenced by the 5% pre-market rise.
+0.60Medtronic's first-quarter revenues rose 13.7% year-over-year to $9.76 billion, exceeding consensus estimates by 3.02%. — Revenue growth above expectations indicates strong demand across the company's product lines.
+0.50The Cardiovascular segment showed strong performance with $3.93 billion in revenue, including a 29.1% increase in Electrophysiology Therapies. — Significant growth in a primary business segment suggests operational strength and market share gains in a high-value area.
+0.40Continue reading
6 related stories
Top 1 mover · tap to explore
Medtronic's reported revenue growth included a benefit of approximately $570 million due to an extra fiscal week in the quarter. — This provides a caveat to the revenue beat, as a portion of the growth is due to a calendar anomaly rather than purely organic demand.
-0.20Which stocks this story touches
Company reported first-quarter earnings and revenues that beat consensus estimates, with shares rising nearly 5% pre-market.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
24/7 Wall Street
4h ago
